DNA
Ginkgo Bioworks Holdings, Inc.
There isn't enough reported data to score DNA yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DNA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DNA's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DNA PE Valuation
DNA has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DNA's losses to grow, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.19 | +$1.90 |
| Q2 2026 | -$5.00 | +$0.72 |
| Q1 2026 | -$5.35 | +$3.67 |
| Q4 2025 | -$5.64 | +$4.90 |
| Q3 2025 | -$6.09 | +$6.59 |
| Q2 2025 | -$5.72 | +$12.28 |
| Q1 2025 | -$9.02 | +$8.18 |
| Q4 2024 | -$10.54 | +$7.86 |
DNA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.7M | -29% |
| Q2 2026 | $20.2M | -59% |
| Q1 2026 | $19.5M | -60% |
| Q4 2025 | $33.4M | -24% |
| Q3 2025 | $38.8M | -56% |
| Q2 2025 | $49.6M | -12% |
| Q1 2025 | $48.3M | +27% |
| Q4 2024 | $43.8M | +26% |
DNA's revenue has slid since its 2022 peak: $28M last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -157% | +74 points |
| Q2 2026 | -290% | -158 points |
| Q1 2026 | -367% | -182 points |
| Q4 2025 | -212% | +24 points |
| Q3 2025 | -232% | -170 points |
| Q2 2025 | -132% | +265 points |
| Q1 2025 | -184% | +285 points |
| Q4 2024 | -236% | +276 points |
DNA's operating margin was −157% last quarter, up 74 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over DNA on profitability, with a higher operating margin.
DNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.3M | +$1.3M |
| Q2 2026 | -$46.9M | -$6.6M |
| Q1 2026 | -$48.6M | +$10.5M |
| Q4 2025 | -$47.7M | +$8.5M |
| Q3 2025 | -$31.6M | +$87M |
| Q2 2025 | -$40.3M | +$71.1M |
| Q1 2025 | -$59.1M | +$36.8M |
| Q4 2024 | -$56.1M | +$5.1M |
DNA has burned cash in almost every quarter: −$174M over the past year, against −$187M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
DNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.9M shares |
| 1 year | +15% | +8.3M shares |
| 3 years | +31% | +15.2M shares |
| 5 years | +99% | +31.8M shares |
DNA has 64M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DNA Net Leverage
DNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.4 | Neutral |
| Stochastic | 37.8 | Neutral |
DNA's weekly RSI is 53 (neutral) and its Stochastic is 38 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DNA PE vs Healthcare Sector
DNA has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.1 | 8% below |
| 20 week MA | $9.13 | 12% above |
| 50 week MA | $8.69 | 18% above |
| 100 week MA | $9.47 | 8% above |
| 200 week MA | $27.5 | 63% below |
DNA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $414.8 | $426.8 | +2.9% |
| 2022 | $426.8 | $66.4 | -84% |
| 2023 | $66.4 | $67.6 | +1.8% |
| 2024 | $67.6 | $9.66 | -86% |
| 2025 | $9.66 | $8.40 | -13% |
| 2026 YTD | $8.40 | $10.2 | +22% |
DNA has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.